title: Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
abstract: Twenty-six cycles of high-dose ifosfamide + mesna (HD-IFO + M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO + M over 24 h appeared to be the best tolerated. One partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.
authors.affiliation: Department of Chemotherapy, University of Vienna, Austria.
authors.forename: G G
authors.initials: GG
authors.lastname: Steger
authors.forename: C
authors.initials: C
authors.lastname: Dittrich
authors.forename: O
authors.initials: O
authors.lastname: Schlappack
authors.forename: R
authors.initials: R
authors.lastname: Mader
authors.forename: C
authors.initials: C
authors.lastname: Herold
authors.forename: W P
authors.initials: WP
authors.lastname: Brade
authors.forename: A
authors.initials: A
authors.lastname: Keller
authors.forename: K
authors.initials: K
authors.lastname: Moser
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects*; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged
chemical_list: D008623:Mercaptoethanol; D015080:Mesna; D007069:Ifosfamide